Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic's balloon kyphoplasty system best for vertebral compression fractures – study

This article was originally published in Clinica

Executive Summary

Medtronic's KyphX balloon kyphoplasty system is better for treating vertebral compression fractures than non-surgical care, the largest study on the technique to date has found. The 300-patient trial met its primary endpoint, change in short-form 36 physical component summary score – there was a significant improvement in kyphoplasty-treated patients compared with the control group (7.2-point and 2-point improvements, respectively). There was no difference in the frequency of adverse events between the groups. Balloon kyphoplasty is a minimally-invasive procedure that uses a balloon to restore vertebral height, followed by injected bone filler material to stabilise fractured vertebrae. The findings were published online in The Lancet on February 25.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT040891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel